Takayuki Ohkuri

Asahikawa Medical College Hospital — Japan

Immunology and Microbiology · Life Sciences

25h-index3.0kcitations110works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(42), Immune Cell Function and Interaction(27), Cancer Immunotherapy and Biomarkers(19), Immune cells in cancer(18), interferon and immune responses(16)

Publications110 total

Figure 1 from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Figure 2 from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Figure S3 from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Figure S2 from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Table S1 from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Figure S1 from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Figure S4 from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Figure 4 from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Data from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Figure 3 from Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
2025Open Access
Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer
Cancer Research Communications·2025Open Access
Synergistic activation of STING and CD40 in the tumor microenvironment enhances CD8+ T-cell-dependent antitumor immunity
Biochemical and Biophysical Research Communications·2025· 1 citedOpen Access
ROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma
Cancers·2025Open Access
Tumor-promoting function of paternally expressed gene 10 and its immunogenicity in inducing anti-tumor helper T cells in head and neck squamous cell carcinoma
Cancer Immunology Immunotherapy·2025Open Access
Differences in <scp>PD</scp>‐<scp>L1</scp>, <scp>PD</scp>‐<scp>L2</scp>, and <scp>EGFR</scp> Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study
Head & Neck·2025· 2 citedOpen Access
Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer
Cancers·2024Open Access
Immunotherapy targeting tumor‐associated antigen in a mouse model of head and neck cancer
Head & Neck·2024· 5 citedOpen Access
Soluble <scp>CD27</scp> as a predictive biomarker for intra‐tumoral <scp>CD70</scp>/<scp>CD27</scp> interaction in nasopharyngeal carcinoma
Cancer Science·2024· 6 citedOpen Access
NF9 peptide specific cytotoxic T lymphocyte clone cross react to Y453F mutation of SARS-CoV-2 virus spike protein
Immunological Medicine·2024· 1 citedOpen Access
SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity
Heliyon·2023· 2 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Akemi Kosaka(27), Hiroya Kobayashi(21), Toshihiro Nagato(20), Takumi Kumai(18), Yasuaki Harabuchi(18), Hidemitsu Kitamura(17), Takashi Nishimura(16), Kenzo Ohara(16), Kensuke Oikawa(16), Daiko Wakita(13), Kenji Chamoto(12), Esteban Celis(12), Hideho Okada(10), Kei Ishibashi(10), Naoko Aoki(9), Shohei Harabuchi(9), Ryusuke Hayashi(9), Marino Nagata(8), Yuki Yajima(8), Yuji Togashi(7)